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Abstract
Background: Recent studies have investigated the contribution of copy number variants (CNVs) to disease
susceptibility in a multitude of complex disorders, including systemic lupus erythematosus, Crohn’s disease, and
various neurodevelopmental disorders. Relatively few CNV studies, however, have been conducted on
pharmacologic phenotypes even though these structural variants are likely to play an important role. We
developed a genome-wide method to identify CNVs that contribute to heterogeneity in drug response, focusing
on drugs that are widely used in anticancer treatment regimens.
Results: We conducted a comprehensive genome-wide study of CNVs from population-scale array-based and
sequencing-based surveys by analyzing their effect on cellular sensitivity to platinating agents and topoisomerase II
inhibitors. We identified extensive CNV regions associated with cellular sensitivity to functionally diverse
chemotherapeutics, supporting the hypothesis that variation in copy number contributes to variation in drug
response. Interestingly, although single nucleotide polymorphisms (SNPs) tag some of the CNVs associated with
drug sensitivity, several of the most significant CNV-drug associations are independent of SNPs; consequently, they
represent genetic variations that have not been previously interrogated by SNP studies of pharmacologic
phenotypes.
Conclusions: Our findings demonstrate that pharmacogenomic studies may greatly benefit from the study of
CNVs as expression quantitative trait loci, thus contributing broadly to our understanding of the complex traits
genetics of CNVs. We also extend our PACdb resource, a database that makes available to the scientific community
relationships between genetic variation, gene expression, and sensitivity to various drugs in cell-based models.
Background
Copy number variants (CNVs) have received consider-
able attention in recent years as studies have implicated
them in a wide range of complex human phenotypes,
including susceptibility to HIV-1/AIDS [1], Crohn’sd i s -
ease [2], and various autoimmune disorders. The sys-
tematic assessment of their role in the etiology of
complex disease has been predicated on improvements
in genotyping technologies (including SNP-based geno-
typing arrays and clone-based comparative genomic
hybridization) and on advances in algorithms for copy
number analysis [3]. Genome-wide surveys of CNVs
[4,5] have sought to produce a comprehensive map to
enable disease association studies, but a recent compre-
hensive study reports a somewhat disappointing finding
that CNVs are likely to make a relatively minor contri-
bution to the genetic basis of complex traits [6], particu-
larly disease susceptibility.
While the study of the contribution of CNVs to drug
response has lagged behind the investigation of their
contribution to disease risk, there have been some nota-
ble findings coming out of candidate gene approaches.
The gene CYP2D6 encodes an enzyme to which the
metabolism of a large number of drugs, such as antide-
pressants, neuroleptics, analgetics and anticancer drugs,
is attributed. It has been demonstrated that CYP2D6
m a yo c c u ri nC N V so f0t o1 3c o p i e s[ 7 ] .S t u d i e sh a v e
shown that copy number for this gene affects the plasma
levels of the active metabolite of tamoxifen, namely
endoxifen, so that ultra-rapid metabolizers who carry
* Correspondence: edolan@medicine.bsd.uchicago.edu; ncox@medicine.bsd.
uchicago.edu
1Section of Genetic Medicine, Department of Medicine, University of
Chicago, 900 East 57th Street, Chicago, IL 60637, USA
2Section of Hematology/Oncology, Department of Medicine, University of
Chicago, 900 East 57th Street, Chicago, IL 60637, USA
Full list of author information is available at the end of the article
Gamazon et al. Genome Biology 2011, 12:R46
http://genomebiology.com/2011/12/5/R46
© 2011 Gamazon et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.more than two copies of the gene show much higher
levels of endoxifen than those who carry the regular
copy number for the gene [8]. Higher CYP2D6 activity
due to gene amplification has also been shown to pre-
dispose to life-threatening opioid intoxication [9].
Another drug metabolizing cytochrome P450 gene,
CYP2A6, also occurs in variable copy number. CYP2A6
encodes an enzyme that metabolizes several drugs,
including nicotine and its metabolite cotinine. Increased
CYP2A6 activity has been shown to be responsible for
increased risk for nicotine addiction [10] and for
tobacco-related cancers. The SULT family of Phase II
conjugating enzymes, particularly that encoded by
SULT1A1, has been the subject of extensive pharmaco-
genetic studies that show the importance of CNVs as a
genetic source of variability in the metabolic activity of
these enzymes. SULT pharmacogenomic studies [11]
have highlighted CNV-based mechanisms that lead to
increased risk for chemical carcinogenesis and adverse
drug reactions. Glutathione S-transferase (GST), also a
phase II family of conjugation enzymes, plays an impor-
tant role in the detoxification of drugs. Studies have
shown that homozygous deletion of GSTM1 is corre-
lated with increased cancer risk and with better treat-
ment outcome [12,13]. These findings and related
developments highlight the necessity of incorporating
copy number analysis in elucidating the genetic under-
pinnings of drug response.
The recently released catalog [4] from an extensive
survey of copy number regions assayed in cell lines
from the International HapMap project and the subse-
quent study of genomic structural variants based on
whole genome DNA sequencing data (the 1000 Gen-
omes Project) [14] allow for new pharmacogenomic dis-
coveries and for deep insights into the genetic basis of
pharmacologic phenotypes, which to date has largely
been based on studies of SNPs [15]. In whole-genome
studies using lymphoblastoid cell lines (LCLs), cellular
sensitivity to drug [16] as well as gene expression phe-
notypes [17] have been shown to be heritable [18] and
to include a significant genetic component. Although
many CNV pharmacogenetic studies have focused on
pharmacokinetic genes, we chose to evaluate pharmaco-
dynamic genes using an LCL-based model. Studies in
our laboratory have generated a rich resource of phar-
m a c o l o g i cd a t a[ 1 9 ]o naw i d ea r r a yo fc h e m o t h e r a p e u -
tic agents using the HapMap cell lines, enabling us to
conduct a systematic analysis of the role of CNVs for a
variety of anticancer drugs.
Results
Genome-wide association studies
LCLs from unrelated CEU samples were phenotyped for
cellular sensitivity to the four chemotherapeutic drugs
included in our study: carboplatin [20], cisplatin [21],
daunorubicin [22], and etoposide [16]. We conducted
genome-wide association scans using drug IC50 as a
quantitative trait.
A total of 5,238 CNVs from an array-based study [4]
were evaluated in genome-wide association studies
(GWAS) against cellular sensitivity drug phenotypes. Of
these CNVs, 77% are deletions (0, 1, or 2 copy number),
16% are amplifications (2, 3, or 4 copy number), and the
remainder are multi-allelic (greater than 3 diploid copy
number genotypes) [4]. At the nominally significant
threshold of P < 0.05, we identified 67 CNVs associated
with carboplatin IC50, 70 CNVs with cisplatin IC50,7 3
CNVs with daunorubicin IC50,a n d1 1 3C N V sw i t he t o -
poside IC50.
Genomic characterization of drug susceptibility-
associated CNVs
We further evaluated the genomic characteristics of
these drug susceptibility-associated CNVs for their size
and type (deletion versus amplification). In general,
there is little (Pearson) correlation between the size of a
CNV and its association with cellular sensitivity to car-
boplatin (r = 0.020), cisplatin (r = 0.008), daunorubicin
(r = 0.054) and etoposide (r = 0.024). We did, however,
observe that the top CNVs associated (P < 0.05) with
IC50 for daunorubicin are significantly smaller (average
size of 10.6 kb) than expected (average size of 14 kb)
from the full set of CNVs included in our study; etopo-
side-associated CNVs are, in contrast, close to expecta-
tion (average size of 13.4 kb). The CNVs associated with
carboplatin and cisplatin IC50 (average size of 11.2 kb
and 11.4 kb, respectively) are significantly smaller than
expected.
Sixty-two of the 67 carboplatin-associated CNVs (P <
0.05) are biallelic (that is, deletions or amplifications);
the remaining five CNVs are multi-allelic CNVs (that is,
defined as having more than three CNV genotypes).
Deletions are significantlym o r ef r e q u e n t( 8 5 % )t h a n
duplications among the carboplatin-associated CNVs.
Similarly, all but 4 of the 70 cisplatin-associated CNVs
(P < 0.05) are biallelic. The top cisplatin-associated
CNVs are significantly more likely to be deletions (87%)
than duplications.
All but 9 etoposide-associated CNVs (P <0 . 0 5 )a r e
biallelic; 69 out of the 73 daunorubicin-associated CNVs
(P < 0.05) are biallelic. Nearly 82% of the daunorubicin-
associated CNVs and 82% of the etoposide-associated
CNVs are deletions.
Drug susceptibility-associated CNVs are enriched for
expression quantitative trait loci
We observed that no exons overlap the genomic regions
defined by the top associated CNVs for each anticancer
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do not act to disrupt coding sequence. We thus
hypothesized that these CNVs act to influence gene reg-
ulation. We evaluated the functional import of the drug
susceptibility-associated CNVs by considering their
effect on global gene expression. At an expression asso-
ciation threshold of P < 0.0001, 60% (N = 40) of the top
CNVs associated with carboplatin (P < 0.05) were found
to be expression quantitative trait loci (eQTLs). Interest-
ingly, two of the top carboplatin-associated CNVs
(CNVR3882.1 on chromosome 8 and CNVR666.1 on
chromosome 2) predict the expression of SELL.W e
found that SELL expression level is also significantly
correlated with carboplatin IC50 (P = 0.02) in the CEU
samples. We identified several target genes of carbopla-
tin-associated CNVs (as eQTLs) whose expression levels
were significantly correlated (after multiple testing cor-
rection [23], false discovery rate (FDR) <0.05) with car-
boplatin IC50, including PHGDH, MYO1B, TGFBR2, and
PRF1. Similarly, nearly 56% (N = 39) of the cisplatin-
associated CNVs (P < 0.05) were associated with the
transcript level of genes as eQTLs. We found a target
gene, MAST4, for two cisplatin-associated CNVs
(CNVR2968.1 on chromosome 6 and CNVR7881.1 on
chromosome 20). MAST4 trends toward significance (P
= 0.06) with cisplatin IC50 in the CEU samples. A target
gene (C4A at P =8 . 2×1 0
-6) for a cisplatin-associated
CNV eQTL (CNVR4748.1 on chromosome 10) was
found to be significantly correlated (after multiple test-
ing correction [23], FDR <0.05) with cisplatin IC50.
Restricting our analysis to biallelic CNVs, we found,
through simulations, that the top CNVs, for each plati-
nating agent, are significantly enriched for eQTLs rela-
tive to frequency-matched SNPs (enrichment P < 0.05).
The eQTL enrichment holds at a lower P-value thresh-
old (P =1 0
-6) used to define an eQTL, showing the
robustness of our observation to the definition of eQTL.
See Materials and methods for details on the simulation
procedure.
Of the top CNVs associated with etoposide IC50 (P <
0.05), 76% (N = 86) were found to be eQTLs. Of these
CNV eQTLs, eight share UBA1 as a target gene (P < 9.7
×1 0
-5). Two target genes (PLEKHG6 at P =1 . 3×1 0
-6
and WSB2 at P =8 . 0×1 0
-5) for etoposide-associated
CNV eQTLs (CNVR4784.1 on chromosome 10 and
CNVR1874.1 on chromosome 4, respectively) were
found to be significantly correlated with etoposide IC50
(FDR < 0.01) [23]. Nearly 52% (N = 38 of the top CNVs
associated with daunorubicin IC50 (P < 0.05) were
eQTLs. We identified two daunorubicin-associated
CNVs (CNVR479.2 and CNVR332.1 on chromosome 1)
predicting the expression of HIST1H4A (P <6 . 7×1 0
-5);
we also found the expression level of this gene to be
correlated (P =3 . 7×1 0
-8) with daunorubicin IC50 in
the CEU samples. We identified several target genes
(including PAPLN at P =3 . 3×1 0
-5 and KLF12 at P =
6.1 × 10
-5) for daunorubicin-associated CNV eQTLs
(CNVR2616.1 on chromosome 5 and CNVR948.1 on
chromosome 2, respectively) whose expression levels
were significantly correlated (after multiple testing cor-
rection [23], FDR < 0.05) with daunorubicin IC50.
As in the case of the platinating agents, we found,
through simulations, that the top CNVs for each topoi-
somerase II inhibitor are more likely to be eQTLs than
frequency-matched SNPs (enrichment P < 0.05).
Functional characterization of transcripts cis-regulated by
deletions from whole genome sequencing data
Given the observed high proportion of deletions
among CNVs associated with cellular sensitivity to
chemotherapeutic agents, wes o u g h ta d d i t i o n a lf u n c -
tional support for the role of CNVs as transcriptional
regulators from whole genome sequencing data coming
out of the 1000 Genomes project, which characterized
the CNV deletions with Gencode/ENCODE transcripts
[14]. The resulting enlarged catalog of CNVs (with an
initial focus on deletions) included CNVs of size 50 bp
or larger mapped at single nucleotide resolution. We
identified 376 transcripts to which CNV deletions were
annotated [14] (by Gencode/ENCODE) as influencing
(cis-regulating) transcription and/or translation. We
proceeded to test the 376 transcripts for their role in
predicting cellular sensitivity to chemotherapeutics. At
P < 0.05, we found 21 transcript correlations with car-
boplatin, 15 with cisplatin, 23 with daunorubicin, and
21 with etoposide (see Table 1). Three transcripts
(MOXD1, RCC1, SULF2) were significant after multiple
testing adjustment (padj < 0.05, Bonferroni). Remark-
ably, the three transcripts were the only CNV deletions
associated with all four agents at the nominal P <0 . 0 5
threshold (Figure 1).
Drug susceptibility-associated CNVs are independent of
drug susceptibility-associated SNPs
We investigated to what extent the CNVs associated
with cellular sensitivity to chemotherapeutic agents may
already be interrogated by SNP-based GWAS through
linkage disequilibrium [6]. We found that the top CNV
(CNVR1616.1) associated with carboplatin IC50 (P =5×
10
-4) is not well-tagged by SNPs. Indeed, the best proxy
SNP for this CNV on chromosome 3 is rs967422 (at r
2
= 0.075). We found that the same CNV is also asso-
ciated with cisplatin IC50 (P =6 . 5×1 0
-3). Another cis-
platin-associated CNV (P =5 . 5×1 0
-3), CNVR7870.1,i s
also not well-tagged; the best proxy SNP, rs915049, tags
the CNV at a low r
2 = 0.11. In each case, the best proxy
SNP, in contrast to the ‘tagged’ drug susceptibility-asso-
ciated CNV, shows no evidence of being associated with
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threshold of P = 0.05.
In the case of the topoisomerase II inhibitors, of the
CNVs showing association with both etoposide and dau-
norubicin (P < 0.05), we found two - CNVR7205.1 and
CNVR3293.1 - that are only modestly tagged (by
rs563079 at r
2 =0 . 7 7a n drs17166803 also at r
2 =0 . 7 7 ,
respectively). Neither rs563079 nor rs17166803 is asso-
ciated with etoposide or daunorubicin IC50. In contrast,
CNVR2930.1, which is one of two etoposide-associated
CNVs predicting the expression of CCND1 (expression
P =2 . 4×1 0
-7), is perfectly tagged (r
2 =1 )b y
rs9500270. We identified a daunorubicin-associated
CNV (CNVR2766.1; P =3 . 7×1 0
-3) for which the best
proxy SNP, rs10484327, tags the CNV at only r
2 = 0.11.
Table 1 Nominally significant (P < 0.05) gene expression
correlations with cellular sensitivity to chemotherapeutic
agents
Gene Drug P-value Chromosome
AKT1S1 Carboplatin 0.04497 19
AKT1S1 Daunorubicin 0.01149 19
AKT1S1 Etoposide 0.00610 19
ALKBH8 Daunorubicin 0.01151 11
AMY1A Etoposide 0.03933 1
AMY2A Etoposide 0.03933 1
ANKLE1 Carboplatin 0.03017 19
ANKLE1 Daunorubicin 0.01706 19
ANKRD36B Daunorubicin 0.02380 2
BCLAF1 Daunorubicin 0.01498 6
C13orf3 Carboplatin 0.00830 13
C13orf3 Cisplatin 0.01980 13
C13orf3 Daunorubicin 0.00572 13
C18orf1 Cisplatin 0.00398 18
CAB39L Etoposide 0.04179 13
DIS3L2 Daunorubicin 0.03077 2
DNAJC5 Carboplatin 0.00166 20
DNAJC5 Cisplatin 0.04058 20
FBRS Carboplatin 0.00661 16
FGFR4 Carboplatin 0.00556 5
FKBP14 Carboplatin 0.03912 7
FLI1 Carboplatin 0.04735 11
FLI1 Daunorubicin 0.00314 11
FLI1 Etoposide 0.04230 11
GALNT1 Daunorubicin 0.00065 18
GPR107 Etoposide 0.00674 9
GPR137 Carboplatin 0.00616 11
GPR137 Cisplatin 0.00828 11
GPR137 Etoposide 0.01493 11
GPR144 Etoposide 0.04526 9
GSPT1 Carboplatin 0.04002 16
GSPT1 Cisplatin 0.01429 16
HLA-DQA1 Daunorubicin 0.00946 6
HLA-DQA1 Etoposide 0.00022 6
IGLV3-21 Carboplatin 0.04800 22
MOXD1 Carboplatin 0.00002 6
MOXD1 Cisplatin 0.00002 6
MOXD1 Daunorubicin 0.03454 6
MOXD1 Etoposide 0.00007 6
MTA1 Etoposide 0.01401 14
NCOA1 Daunorubicin 0.04278 2
NEK6 Carboplatin 0.04050 9
NUB1 Etoposide 0.02671 7
PPP1R3B Cisplatin 0.03039 8
PTP4A2 Carboplatin 0.01930 1
PTP4A2 Cisplatin 0.01182 1
PTP4A2 Etoposide 0.03348 1
RCC1 Carboplatin 0.01252 1
RCC1 Cisplatin 0.01722 1
Table 1 Nominally significant (P ?<? 0.05) gene expres-
sion correlations with cellular sensitivity to chemothera-
peutic agents (Continued)
RCC1 Daunorubicin 0.00002 1
RCC1 Etoposide 0.01358 1
RNF103 Daunorubicin 0.02655 2
RPN2 Daunorubicin 0.01206 20
SLC10A7 Daunorubicin 0.00481 4
SLC4A8 Cisplatin 0.02189 12
SLC4A8 Etoposide 0.00248 12
SMPD4 Daunorubicin 0.02446 2
SNRK Carboplatin 0.00396 3
SNRK Cisplatin 0.00479 3
SNRK Daunorubicin 0.02429 3
SULF2 Carboplatin 0.00002 20
SULF2 Cisplatin 0.00053 20
SULF2 Daunorubicin 0.00014 20
SULF2 Etoposide 0.00000 20
TBC1D22A Cisplatin 0.03807 22
TBL1XR1 Carboplatin 0.04028 3
TFDP1 Cisplatin 0.04967 13
TNK2 Carboplatin 0.01901 3
TNK2 Daunorubicin 0.00431 3
TNK2 Etoposide 0.01159 3
TYRO3 Etoposide 0.02840 15
UPK3B Cisplatin 0.02839 7
WDR90 Daunorubicin 0.02575 16
WDR90 Etoposide 0.00111 16
ZDHHC4 Daunorubicin 0.02463 7
ZFAND2A Daunorubicin 0.00227 7
ZFAND2A Etoposide 0.03567 7
ZNF277 Etoposide 0.04521 7
ZNF331 Carboplatin 0.02122 19
ZNF664 Carboplatin 0.04722 12
Transcripts are cis-regulated by CNVs identified from whole-genome
sequencing.
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PACdb [24] is a large-scale, publicly available genomic
database, which to date holds the results of our SNP-
based GWAS on the following chemotherapeutic agents:
carboplatin, cisplatin, etoposide, daunorubicin, and
cytarabine. PACdb implements a structured repository
for incorporating other datasets, including information
on other drugs, gene expression profiling, and cellular
phenotypes. GWAS were initially conducted using SNP
genotype data made available by the International Hap-
Map project. We expanded PACdb to include the
results of our CNV-based GWAS on carboplatin, cispla-
tin, etoposide, and daunorubicin. Furthermore, the
results of eQTL mapping of HapMap CNVs to tran-
scriptional expression are made available in the eQTL
repository SCAN. Figure 2 shows a schematic diagram
of our approach to the discovery of CNVs associated
with sensitivity to drug and to the identification of such
CNVs that act as eQTLs; it also illustrates the genomic
resources we have made publicly available to the scienti-
fic community.
CNVs and drug classes
We evaluated to what extent the top CNV associations
for a given drug would overlap with the top CNV asso-
ciations for another drug belonging to the same che-
motherapeutic drug class, defined in terms of
mechanism of action. At the suggestive threshold of P <
0.05, of the CNVs showing association with carboplatin
IC50, 16% (n = 11) were also associated with cisplatin
MOXD1
RCC1
SULF2
carboplatin cisplatin etoposide daunorubicin
Figure 1 Three transcripts cis-regulated by CNVs identified by whole genome sequencing data predict cellular sensitivity to
functionally diverse chemotherapeutics. Through ENCODE/Gencode annotation, 376 genes were recently identified [12] to be cis-regulated
by CNV deletions. At P < 0.05, we found 21 gene expression correlations with carboplatin, 15 with cisplatin, 23 with daunorubicin, and 21 with
etoposide. Three transcripts (MOXD1 on chromosome 6, RCC1 on chromosome 1, SULF2I on chromosome 20) were significant after multiple
testing adjustment (padj < 0.05) and were the only CNV deletions associated with all four agents at the nominal P < 0.05 threshold. The plots
show level of expression (x axis) and IC50 (y axis).
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-10)
between the (two) sets of CNVs associated with cellular
sensitivity to the platinating agents. Figure 3 illustrates a
duplication (CNVR7826_full on chromosome 20) that is
associated with sensitivity to carboplatin (Figure 3a) and
to cisplatin (Figure 3b); note that the observed genotype
associations with the platinums have concordant direc-
tion. Furthermore, the CNV is an eQTL predicting the
expression of GSR (P =4 . 6 7×1 0
-5)a n dSPARC (P =
4.70 × 10
-5). Remarkably, the expression levels of these
target mRNAs, GSR (P = 0.045) and SPARC (P = 0.004),
are correlated with carboplatin IC50; similarly, GSR (P =
0.005) and SPARC (P = 0.005) are correlated with cispla-
tin IC50. Glutathione reductase (GSR) has been impli-
cated in several studies of platinum sensitivity [25,26].
In the case of the topoisomerase II inhibitors, 12% of
the etoposide-associated CNVs were found to associate
with daunorubicin IC50, and the observed overlap is still
quite significant (P =2 . 7×1 0
-10). The slightly greater
percentage of overlap for the platinating agents is not
due to higher phenotypic correlation (platinating agents
(r = 0.52) versus topoisomerase II inhibitors (r = 0.69)).
Real-time PCR validation
We sought additional experimental support for the
genes targeted by multiple CNVs associated with drug
susceptibility. We identified two etoposide-associated
CNV eQTLs that share CCND1 as a target gene
(expression P =2 . 4×1 0
-7). The over-expression of
CCND1 has been shown to be associated with the up-
regulation of the GST-π gene, increasing the sensitivity
of a cancer cell line to etoposide [27]. We found
CCND1 expression to be significantly correlated with
etoposide IC50 (P =7 . 8×1 0
-6)i nt h eC E Us a m p l e s .
After multiple testing correction, the gene remained
significant (q-value = 0.0027). We subsequently con-
ducted functional validation of the role of CCND1
expression in altering sensitivity to etoposide by per-
forming real-time quantitative-PCR assays in an inde-
pendent set of 52 CEPH LCLs (Figure 4; see Table S1
in Additional file 1 for the real-time PCR data on
CCND1). Consistent with the direction of effect in the
CEU samples, increased CCND1 mRNA levels resulted
in increased IC50 (P = 0.05) in the validation set. Thus,
increasing CCND1 expression confers resistance to
etoposide.
Discussion
Understanding in a comprehensive manner the genetic
risk factors contributing to variation in drug response is
a crucial component of the realization of personalized
medicine. The drugs evaluated in our study are widely
used in the treatment of many cancer types, including
ovarian, colorectal, testicular, and lung; all are associated
with particular toxicities and resistance. Although SNPs
have long been used in association studies to elucidate
the effect of genetic polymorphisms on drug response,
CNVs have been relatively understudied. Recent
dCNVs
dSNPs
eCNVs
GWAS
eQTL Mapping
Figure 2 A schematic of the approach to the discovery of drug susceptibility-associated CNVs. We added to PACdb the CNV associations
with cellular sensitivity to the chemotherapeutic agents. Note that some drug-associated CNVs (dCNVs) are poorly interrogated by SNPs and are
thus independent of drug-associated SNPs (dSNPs). SCAN includes the results of eQTL mapping of CNVs to transcriptional expression.
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that these structural variants are a common phenom-
enon in the human genome [5]. With rapid advances in
methods that facilitate their assay and analysis, variation
in copy number for genes encoding drug metabolizing
enzymes has been increasingly implicated for their dra-
matic consequences on responsiveness to drugs. Such
CNVs have been observed to alter gene dosage and are
thus likely to play an important role in determining
drug efficacy or toxicity.
In this study, we set out to utilize recent develop-
ments in the assay of CNVs in recent population-scale
projects, including an extensive comparative genomic
hybridization-based catalog of CNVs [4] and a map of
structural variants based on whole genome DNA
sequencing data (the 1000 Genomes Project) [14], in
order to evaluate the role of CNVs in cellular sensitivity
to chemotherapeutic agents. The cell lines for the sam-
ples express a sizable part of the genome [28], thus
enabling the investigation of genes represented in
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Figure 3 A CNV associated with cellular sensitivity to both carboplatin and cisplatin. We identified an amplification CNV, CNVR7826_full on
chromosome 20, that is associated with both carboplatin sensitivity (a) (P = 0.0056) and cisplatin sensitivity (b) (P = 0.0023). The x-axis is the
copy number (3 or 4) for the CNV; the y-axis is the log2-transformed IC50.
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is clearly necessary for understanding chemotherapeutic
response, the importance of germline genetic variation
in drug sensitivity has also been consistently demon-
strated [15].
For each drug included in our study, we found that
the top associated CNVs are more likely to act as
eQTLs and predict transcript levels than minor allele
frequency (MAF)-matched SNPs. The overlap of the
drug susceptibility-associated CNVs with expression-
associated CNVs (eCNVs) is greater than is expected,
based on simulation studies. Consistent with a previous
report [6], CNVs associated with cellular sensitivity to
drug treatment are not likely to overlap exons, suggest-
ing that they act not to disrupt coding sequence but to
regulate gene expression. The high proportion of eQTLs
among the CNVs associated with cellular sensitivity to
each of the drugs further supports the hypothesis that
these CNVs mediate their phenotypic consequences
through their effect on the transcriptome. Genome-wide
studies of pharmacologic phenotypes, such as response
to antineoplastic agents, may benefit from studies of
CNVs as eQTLs.
This study, to our knowledge, is the first comprehen-
sive genome-wide study of the effect of CNVs, from the
most extensive array-based and sequencing-based sur-
veys of these structural variants, on pharmacologic phe-
notypes. In contrast to a recent disease susceptibility
study that concluded that most CNVs that are well-
typed have been indirectly explored by SNP studies [6],
we found a number of CNVs associated with drug sensi-
tivity that are independent of SNPs. These CNVs there-
fore constitute novel genetic variations that have not
been previously interrogated by SNP-based GWAS of
pharmacologic phenotypes. Our discovery of drug sus-
ceptibility-associated variations, in the form of CNVs,
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Figure 4 The relationship between CCND1 expression and etoposide IC50 in the discovery set and in an independent replication set of
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Page 8 of 12that are independent of previous SNP findings and that
show evidence for altering gene expression as eQTLs,
suggests that CNVs should be included in comprehen-
sive pharmacogenomic studies.
Candidate pharmacogenetic studies on drug metabo-
lism-related genes, namely CYP2D6, CYP2A6, SULT1A1
and GSTM1, have documented the effect of CNVs on
gene activity. Our results strongly support the necessity
of integrating both SNP and CNV data to tighten the
genotype-phenotype gap in pharmacogenetic studies.
While the functional validation we conducted in this
study may not allow robust predictions, the functional
characterization of the effect of CCND1 mRNA level on
cellular sensitivity to etoposide underscores the impor-
tance of considering the role of the transcripts that are
the targets of drug susceptibility-associated CNVs (act-
ing as eQTLs) in conferring drug susceptibility.
We found a significant overlap (P =7 . 7×1 0
-10)
between the CNVs associated with cisplatin and carbo-
platin. Platinating agents share a similar mechanism of
therapeutic action and interact with DNA to form inter-
strand and intrastrand cross-links, leading to cytotoxic
DNA lesions and eventually apoptosis-induced cell
death. Our findings strongly support the hypothesis that
CNV-based mechanisms play a crucial role in determin-
ing platinum sensitivity. Particularly, we identified a
duplication that is associated with cellular sensitivity to
both carboplatin and cisplatin. Furthermore, the CNV
predicts the expression of glutathione reductase (GSR), a
gene that has been the subject of several studies on cis-
platin sensitivity [26,30]. The glutathione pathway is
involved in the metabolism of platinum compounds,
which are subject to inactivation by glutathione conjuga-
tion [27].
A significant level of overlap is also observed with the
topoisomerase II inhibitors. Daunorubicin is a DNA
intercalator that indirectly interacts with topo II while
etoposide binds directly to the enzyme. We identified 14
CNVs associated with both etoposide and daunorubicin
at P < 0.05. The extent of overlap between the platinat-
ing agents (as well as between the topoisomerase II inhi-
bitors) is significantly higher than the level of overlap
across drug classes (7%).
There is a general caveat to our findings concerning
the set of CNVs included in this analysis. The CNVs
tested for association with cellular sensitivity to drugs
may be biased towards genotypeable variants; conse-
quently, many highly complex regions may have been
excluded. Furthermore, our study makes no assertions
about low frequency variants. Nevertheless, our findings
represent the most comprehensive study of the effect of
common CNVs, from the most extensive map of these
variants available, on chemotherapeutic susceptibility to
a wide array of drugs.
Finally, we provide the results of our genome-wide
study of CNVs and sensitivity to chemotherapeutic
agents in a publicly available online database, PACdb.
Analysis results on our cell-based model are easy to
query, which should allow investigators to utilize the
resource as a discovery platform or as a validation tool
for clinical observations.
Conclusions
Our study identified CNVs that predict cellular sensitiv-
ity to an array of chemotherapeutic agents of heteroge-
neous molecular therapeutic action. Importantly, several
of the most significant CNV-drug associations are inde-
pendent of SNPs; thus, these CNVs provide genetic var-
iations that have not been previously explored by SNP-
based GWAS of pharmacologic phenotypes. Further-
more, our findings show that pharmacogenomic studies
may be greatly enhanced by studies of CNVs as eQTLs.
Target genes of CNVs, especially those associated with
multiple independent CNVs associated with drug
response, provide robust gene expression signatures of
chemotherapeutic susceptibility.
Materials and methods
In vitro cellular sensitivity to chemotherapeutic agents
We obtained unrelated HapMap phase II CEU (Utah
residents with ancestry from northern and western Eur-
ope) samples from Coriell Institute for Medical Research
(Camden, NJ, USA). Cell lines were maintained in RPMI
1640 media supplemented with 15% fetal bovine serum
(Hyclone, Logan, UT, USA) and 1% l-glutamine. The
cell lines were passaged three times per week at a con-
centration of 350,000 cells/ml at 37°C in a 95% humidi-
fied 5% CO2 atmosphere. Cellular sensitivity to drugs
was measured in these cell lines with increasing concen-
trations of drug (from carboplatin, cisplatin, daunorubi-
cin, and etoposide). Cell growth inhibition was evaluated
using the alamarBlue™ assay (BioSource International
Inc., Camarillo, CA, USA), as previously described [21].
IC50 (the concentration required to inhibit 50% of cell
growth) was determined by curve fitting of percent cell
survival against concentrations of the drug.
A catalog of CNVs
Recent population-based surveys have mapped thou-
sands of CNVs with increasing resolution. Such surveys
have opened up approaches for modeling the relation-
ship between structural variation and complex traits.
Efforts to catalog these CNVs are necessary to clarify
the functional impact of these variants. Here we utilize
the recent comprehensive survey of CNVs [4] larger
than 1 kb in size in the human genome, assayed in
human LCLs from CEU (Utah residents with ancestry
from northern and western Europe) samples. To
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Page 9 of 12investigate further the effect of deletions and to confirm
our findings on the role of drug-associated CNVs as
eQTLs, we studied the relationship between cis-regu-
lated transcripts (from Gencode/ENCODE functional
annotation) and cellular sensitivity to chemotherapeutics
from a recent comprehensive study based on whole gen-
ome sequencing data of the 1000 Genomes Project [14],
w h i c hm a p p e dC N V so f5 0b po rl a r g e ri ns i z ea t
nucleotide resolution.
Association analysis of CNVs or transcript levels with
cellular sensitivity to drugs
For each CNV, genotypes were tested for association
with cellular sensitivity to each of the drugs separately.
Linear regression was performed between the copy
number genotype (as the independent variable) and
log2-transformed IC50 (as the dependent variable). Ana-
lysis was done in the statistical computing and graphics
software R; the lm function was used to fit linear
models.
Similarly, to examine the relationship between tran-
script level and drug-induced cellular sensitivity, a linear
model was constructed for each drug, as previously
described [19], between log2-transformed gene expres-
sion and log2-transformed IC50. Generally, for multiple
testing adjustment, FDRs were calculated using the q-
value [23] package in R. Unless otherwise stated, an
FDR cutoff <0.05 was used as the statistical significance
threshold.
Mapping CNVs as expression quantitative trait loci
SCAN [29] is an online database that makes publicly
available the results of our eQTL studies, initially on
single base polymorphisms. Global mRNA expression
was assayed using the Affymetrix GeneChip Human
Exon 1.0 ST Array [30]. To map CNVs as genomic loci
influencing the transcriptome, we conducted linear
regression on over 13,000 transcript clusters and the set
of CNVs identified in the HapMap LCLs [31].
Simulation studies
We performed simulations to evaluate enrichment for
eQTLs among the CNVs associated with cellular sensitiv-
ity to the drugs included in our study. To empirically
generate the null distribution, we randomly generated
sets of SNPs of matching minor allele frequency as the
original list of CNVs (see Figure S1 in Additional file 2
for MAF distribution of the biallelic CNVs included in
our study), as previously described [32]. To enable us to
perform simulations conditional on MAF, we constructed
non-overlapping MAF bins, each of width 0.05, using the
MAFs of the SNPs in the HapMap CEU samples. The
null sets were drawn from the combined platform SNPs
(Affymetrix 6.0 and Illumina 1M) as well as from the
entire set of HapMap CEU SNPs. The observed count is
then compared to the empirically generated distribution
to get an empirical P-value for the enrichment.
Functional validation
We obtained 52 unrelated non-HapMap CEPH (Centre
d’Etude du Polymorphisme Humain) samples (indepen-
dent of the discovery cohort consisting of HapMap CEU
samples) from Coriell Institute for Medical Research.
Cellular sensitivity to etoposide phenotype was quanti-
fied as described above with increasing concentrations
of etoposide treatment (0.02 μM, 0.1 μM, 0.5 μM, and
2.5 μM for 72 hours). IC50 was determined for each cell
line. CCND1 mRNA levels were evaluated using a real-
time quantitative PCR assay in the samples using Taq-
Man Gene Expression Assays (Applied Biosystems, Fos-
ter City, CA, USA) on the Applied Biosystems 7500
real-time PCR system. Primer/probes were obtained
from Applied Biosystems. The human beta 2M (huB2M,
beta-2 microglobulin; NM_004048; Applied Biosystems
catalog number 4326319E) was used as endogenous
control. Relative quantification of gene expression uti-
lized the 2
(-ΔΔCt) method [33].
Additional material
Additional file 1: Real-time PCR data on CCND1. The table lists the
real-time PCR. values for CCND1 expression, as measured in the
independent set of 52 cell lines.
Additional file 2: The minor allele frequency distribution of the
biallelic CNVs included in our study. The plot is a histogram of the
minor allele frequency of the biallelic CNVs that were evaluated in our
study.
Abbreviations
bp: base pair; CNV: copy number variant; eQTLs: expression quantitative trait
loci; FDR: false discovery rate; GST: Glutathione S-transferase; GWAS:
genome-wide association studies; LCL: lymphoblastoid cell line; MAF: minor
allele frequency; PCR: polymerase chain reaction; SNP: single nucleotide
polymorphism.
Acknowledgements
This work was funded through Pharmacogenomics of Anticancer Agents
Research (PAAR; U01 GM61393), ENDGAMe (ENhancing Development of
Genome-wide Association Methods) initiative (U01 HL084715), the
Genotype-Tissue Expression project (GTeX) (R01 MH090937), Rare Variants
and Complex Human Phenotypes (U01HG005773), the University of Chicago
Breast Cancer SPORE (P50 CA125183), Specialized Center of Research Grant
from the Leukemia and Lymphoma Society and the University of Chicago
DRTC (Diabetes Research and Training Center; P60 DK20595). RSH received
support from NIH/NIGMS grant K08GM089941, NIH/NCI grant R21 CA139278,
University of Chicago Cancer Center Support Grant (#P30 CA14599), and
Breast Cancer SPORE Career Development Award. The authors are grateful
to Anuar Konkashbaev and Wasim Bleibel for excellent technical assistance.
We acknowledge the Wellcome Trust Case Control Consortium for making
available data about SNP tagging of common CNVs [34].
Author details
1Section of Genetic Medicine, Department of Medicine, University of
Chicago, 900 East 57th Street, Chicago, IL 60637, USA.
2Section of
Gamazon et al. Genome Biology 2011, 12:R46
http://genomebiology.com/2011/12/5/R46
Page 10 of 12Hematology/Oncology, Department of Medicine, University of Chicago, 900
East 57th Street, Chicago, IL 60637, USA.
3Department of Human Genetics,
University of Chicago, 920 East 58th Street, CLSC 5th floor, Chicago, IL 60637,
USA.
Authors’ contributions
ERG conceived the study. ERG, RSH, MED, and NJC designed the
experiments and the analyses and wrote the manuscript. ERG analyzed the
data. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 22 March 2011 Revised: 8 May 2011 Accepted: 25 May 2011
Published: 25 May 2011
References
1. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G,
Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH,
Bradley W, Clark RA, Anderson SA, O’connell RJ, Agan BK, Ahuja SS,
Bologna R, Sen L, Dolan MJ, Ahuja SK: The influence of CCL3L1 gene-
containing segmental duplications on HIV-1/AIDS susceptibility. Science
2005, 307:1434-1440.
2. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P,
Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD,
Rioux JD, Altshuler D, Daly MJ, Xavier RJ: Deletion polymorphism
upstream of IRGM associated with altered IRGM expression and Crohn’s
disease. Nat Genet 2008, 40:1107-1112.
3. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A,
Shapero MH, de Bakker PI, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E,
Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M,
Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D: Integrated
detection and population-genetic analysis of SNPs and copy number
variation. Nat Genet 2008, 40:1166-1174.
4. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J,
Andrews TD, Barnes C, Campbell P, Fitzgerald T, Hu M, Ihm CH,
Kristiansson K, Macarthur DG, Macdonald JR, Onyiah I, Pang AW, Robson S,
Stirrups K, Valsesia A, Walter K, Wei J, Wellcome Trust Case Control
Consortium, Tyler-Smith C, Carter NP, Lee C, Scherer SW, Hurles ME: Origins
and functional impact of copy number variation in the human genome.
Nature 2010, 464:704-712.
5. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H,
Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL,
González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D,
MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K,
Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, et al:
Global variation in copy number in the human genome. Nature 2006,
444:444-454.
6. Wellcome Trust Case Control Consortium, Craddock N, Hurles ME, Cardin N,
Pearson RD, Plagnol V, Robson S, Vukcevic D, Barnes C, Conrad DF,
Giannoulatou E, Holmes C, Marchini JL, Stirrups K, Tobin MD, Wain LV,
Yau C, Aerts J, Ahmad T, Andrews TD, Arbury H, Attwood A, Auton A,
Ball SG, Balmforth AJ, Barrett JC, Barroso I, Barton A, Bennett AJ, Bhaskar S,
et al: Genome-wide association study of CNVs in 16,000 cases of eight
common diseases and 3,000 shared controls. Nature 2010, 464:713-720.
7. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-
Sundberg M: Inherited amplification of an active gene in the cytochrome
P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Proc Natl Acad Sci USA 1993, 90:11825-11829.
8. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW,
Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM,
Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN: The impact of
cytochrome P450 2D6 metabolism in women receiving adjuvant
tamoxifen. Breast Cancer Res Treat 2007, 101:113-121.
9. Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J:
Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N
Engl J Med 2004, 351:2827-2831.
10. Malaiyandi V, Sellers EM, Tyndale RF: Implications of CYP2A6 genetic
variation for smoking behaviors and nicotine dependence. Clin
Pharmacol Ther 2005, 77:145-158.
11. Hebbring SJ, Moyer AM, Weinshilboum RM: Sulfotransferase gene copy
number variation: pharmacogenetics and function. Cytogenet Genome Res
2008, 123:205-210.
12. Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM: The role of
glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J
Cancer 2007, 43:283-290.
13. Müller P, Asher N, Heled M, Cohen SB, Risch A, Rund D: Polymorphisms in
transporter and phase II metabolism genes as potential modifiers of the
predisposition to and treatment outcome of de novo acute myeloid
leukemia in Israeli ethnic groups. Leuk Res 2008, 32:919-929.
14. Mills RE, Walter K, Stewart C, Handsaker RE, Chen K, Alkan C, Abyzov A,
Yoon SC, Ye K, Cheetham RK, Chinwalla A, Conrad DF, Fu Y, Grubert F,
Hajirasouliha I, Hormozdiari F, Iakoucheva LM, Iqbal Z, Kang S, Kidd JM,
Konkel MK, Korn J, Khurana E, Kural D, Lam HY, Leng J, Li R, Li Y, Lin CY,
Luo R, et al: Mapping copy number variation by population-scale
genome sequencing. Nature 2011, 470:59-65.
15. Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS,
McLeod H, Dolan ME: Pharmacogenomic discovery using cell-based
models. Pharmacol Rev 2009, 61:413-429.
16. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, Clark TA, Chen TX,
Schweitzer AC, Blume JE, Cox NJ, Dolan ME: A genome-wide approach to
identify genetic variants that contribute to etoposide-induced
cytotoxicity. Proc Natl Acad Sci USA 2007, 104:9758-9763.
17. Morley M, Molony CM, Weber TM, Devlin JL, Ewens KG, Spielman RS,
Cheung VG: Genetic analysis of genome-wide variation in human gene
expression. Nature 2004, 430:743-747.
18. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr,
Badner JA: Heritability and linkage analysis of sensitivity to cisplatin-
induced cytotoxicity. Cancer Res 2004, 64:4353-4356.
19. Huang RS, Ratain MJ: Pharmacogenetics and pharmacogenomics of
anticancer agents. CA Cancer J Clin 2009, 59:42-55.
20. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME: Genetic variants
associated with carboplatin-induced cytotoxicity in cell lines derived
from Africans. Mol Cancer Ther 2008, 7:3038-3046.
21. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, Chen TX, Schweitzer AC,
Blume JE, Dolan ME: Identification of genetic variants contributing to
cisplatin-induced cytotoxicity by use of a genomewide approach. Am J
Hum Genet 2007, 81:427-437.
22. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL,
Das S, Dolan ME: Genetic variants contributing to daunorubicin-induced
cytotoxicity. Cancer Res 2008, 68:3161-3168.
23. Storey JD, Tibshirani R: Statistical significance for genomewide studies.
Proc Natl Acad Sci USA 2003, 100:9440-9445.
24. Gamazon ER, Duan S, Zhang W, Huang RS, Kistner EO, Dolan ME, Cox NJ:
PACdb: a database for cell-based pharmacogenomics. Pharmacogenet
Genomics 2010, 20:269-273.
25. Ogawa J, Iwazaki M, Inoue H, Koide S, Shohtsu A: Immunohistochemical
study of glutathione-related enzymes and proliferative antigens in lung
cancer. Relation to cisplatin sensitivity. Cancer 1993, 71:2204-2209.
26. Moyer AM, Sun Z, Batzler AJ, Li L, Schaid DJ, Yang P, Weinshilboum RM:
Glutathione pathway genetic polymorphisms and lung cancer survival
after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev
2010, 19:811-821.
27. Bennaceur-Griscelli A, Bosq J, Koscielny S, Lefrère F, Turhan A, Brousse N,
Hermine O, Ribrag V: High level of glutathione-S-transferase pi expression
in mantle cell lymphomas. Clin Cancer Res 2004, 10:3029-3034.
28. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, Spielman RS:
Natural variation in human gene expression assessed in lymphoblastoid
cells. Nat Genet 2003, 33:422-425.
29. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL,
Dolan ME, Cox NJ: SCAN: SNP and copy number annotation.
Bioinformatics 2010, 26:259-262.
30. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, Clark TA, Chen TX,
Schweitzer AC, Blume JE, Cox NJ, Dolan ME: Genetic architecture of
transcript-level variation in humans. Am J Hum Genet 2008, 82:1101-1113.
31. Gamazon ER, Nicolae DL, Cox NJ: A study of CNVs as trait-associated
polymorphisms and as expression quantitative trait loci. PLoS Genet 2011,
7:e1001292.
32. Gamazon ER, Huang RS, Cox NJ, Dolan ME: Chemotherapeutic drug
susceptibility associated SNPs are enriched in expression quantitative
trait loci. Proc Natl Acad Sci U S A 2010, 107:9287-9292.
Gamazon et al. Genome Biology 2011, 12:R46
http://genomebiology.com/2011/12/5/R46
Page 11 of 1233. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods
2001, 25:402-408.
34. Wellcome Trust Case Control Consortium: Genome-wide association study
of copy number variation in 16,000 cases of eight common diseases
and 3,000 shared controls - supplementary information.[http://www.
wtccc.org.uk/wtcccplus_cnv/supplemental.shtml].
doi:10.1186/gb-2011-12-5-r46
Cite this article as: Gamazon et al.: Copy number polymorphisms and
anticancer pharmacogenomics. Genome Biology 2011 12:R46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gamazon et al. Genome Biology 2011, 12:R46
http://genomebiology.com/2011/12/5/R46
Page 12 of 12